{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:37:51Z","timestamp":1791214671309,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd002750","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T00:00:00Z","timestamp":1364428800000}}],"reference-count":29,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002750.pub2","type":"journal-article","created":{"date-parts":[[2013,3,29]],"date-time":"2013-03-29T21:04:34Z","timestamp":1364591074000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Calcium antagonists as an add-on therapy for drug-resistant epilepsy"],"prefix":"10.1002","volume":"2013","author":[{"given":"Mohammad","family":"Hasan","sequence":"first","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Clinical Sciences Centre, University Hospital Aintree Lower Lane, Fazakerley Liverpool UK L9 7AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Pulman","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Clinical Sciences Centre, University Hospital Aintree Lower Lane, Fazakerley Liverpool UK L9 7AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Clinical Sciences Centre, University Hospital Aintree Lower Lane, Fazakerley Liverpool UK L9 7AL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,28]]},"reference":[{"key":"10.1002\/14651858.CD002750.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-0404.1989.tb03724.x","article-title":"Double-blind placebo-controlled evaluation of flunarizine as adjunct therapy in epilepsy with complex partial seizures","volume":"79","author":"Alving","year":"1989","journal-title":"Acta Neurologica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD002750.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0387-7604(12)80052-0","article-title":"Double-blind placebo-controlled trial of flunarizine as add-on therapy in refractory childhood epilepsy","volume":"13","author":"Battaglia","year":"1991","journal-title":"Brain and Development"},{"issue":"3","key":"10.1002\/14651858.CD002750.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00002826-198806000-00005","article-title":"Double-blind placebo-controlled trial with flunarizine in therapy-resistant epileptic patients","volume":"11","author":"Froscher","year":"1988","journal-title":"Clinical Neuropharmacology"},{"issue":"2","key":"10.1002\/14651858.CD002750.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1017\/S0317167100028882","article-title":"Flunarizine as a supplementary medication in refractory childhood epilepsy: a double-blind crossover study","volume":"16","author":"Keene","year":"1989","journal-title":"Canadian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0920-1211(91)90049-L","article-title":"Nimodipine in refractory epilepsy: a placebo-controlled, add-on study","volume":"9","author":"Larkin","year":"1991","journal-title":"Epilepsy Research"},{"issue":"2","key":"10.1002\/14651858.CD002750.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1528-1157.1992.tb02326.x","article-title":"Nifedipine for epilepsy? A double-blind, placebo-controlled trial","volume":"33","author":"Larkin","year":"1992","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD002750.pub2-BIB0007|cit7","first-page":"547","article-title":"Flunarizine as add-on therapy in epilepsy: crossover study versus placebo","volume":"1","author":"Moglia","year":"1986","journal-title":"Functional Neurology"},{"issue":"2","key":"10.1002\/14651858.CD002750.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1528-1157.1984.tb04178.x","article-title":"Double-blind placebo-controlled trial of flunarizine as add-on therapy in epilepsy","volume":"25","author":"Overweg","year":"1984","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0009|cit9","first-page":"153","article-title":"Nimodipine in drug-resistant childhood epilepsy: a double-blind, placebo-controlled trial","volume":"82\/83","author":"Pelliccia","year":"1993","journal-title":"Bolletino Lega Italiana Contro L'Epilessia"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1212\/WNL.44.10.1830","article-title":"Flunarizine for treatment of partial seizures: results of a concentration-controlled trial","volume":"44","author":"Pledger","year":"1994","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S0317167100028870","article-title":"Double-blind cross-over placebo controlled study of flunarizine in patients with therapy resistant epilepsy","volume":"16","author":"Starreveld","year":"1989","journal-title":"Canadian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1528-1157.1985.tb05674.x","article-title":"Open dose-ranging trial of flunarizine as add-on therapy in epilepsy","volume":"26","author":"Binnie","year":"1985","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD002750.pub2-BIB0013|cit13","first-page":"551","article-title":"The use of flunarizine in pediatric epilepsy","volume":"1","author":"Cavazzuti","year":"1986","journal-title":"Functional Neurology"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00192365","article-title":"Rising dose study of safety and tolerance of flunarizine","volume":"49","author":"Handforth","year":"1995","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD002750.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1177\/088307389601100621","article-title":"Add-on therapy with nimodipine in intractable epilepsy of childhood","volume":"11","author":"Malashkhia","year":"1996","journal-title":"Journal of Child Neurology"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0016|cit16","first-page":"119","article-title":"Nimodipine for intractable seizures: a double-blind placebo-controlled crossover study","volume":"33 Suppl 3","author":"Cascino","year":"1992","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.4065\/70.7.623","article-title":"Nimodipine as an add-on therapy for intractable epilepsy","volume":"70","author":"Meyer","year":"1995","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0018|cit18","first-page":"155","article-title":"Nimodipine as adjunctive therapy in refractory epilepsy","volume":"82\/83","author":"Sasso","year":"1993","journal-title":"Bolletino Lega Italiana Contro L'Epilessia"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1528-1157.1993.tb02116.x","article-title":"Increasing plasma concentration tolerability study of flunarizine in comedicated epileptic patients","volume":"34","author":"Treiman","year":"1993","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0020|cit20","unstructured":"Verapamil study in refractory epilepsy http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01126307"},{"issue":"4","key":"10.1002\/14651858.CD002750.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1474-4422(12)70018-2","article-title":"Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial","volume":"11","author":"Bonnett","year":"2012","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0022|cit22","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2010"},{"issue":"9284","key":"10.1002\/14651858.CD002750.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0140-6736(01)05971-2","article-title":"Human epilepsy associated with dysfunction of the brain P\/Q-type calcium channel","volume":"358","author":"Jouvenceau","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1136\/bmj.e281","article-title":"Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance","volume":"344","author":"Nunes","year":"2012","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0025|cit25","volume-title":"Martindale: The extra pharmacopoeia","author":"Reynolds","year":"1993"},{"key":"10.1002\/14651858.CD002750.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"ii2","DOI":"10.1136\/jnnp.2005.069245","article-title":"EEG in the diagnosis, classification, and management of patients with epilepsy","volume":"76","author":"Smith","year":"2005","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD002750.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1345\/aph.1E068","article-title":"Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy","volume":"38","author":"Summers","year":"2004","journal-title":"The Annals of Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD002750.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2007.01.016","article-title":"Calcium channel antagonists: Clinical uses - past, present and future","volume":"74","author":"Triggle","year":"2007","journal-title":"Biochemical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD002750.pub2-BIB0029|cit29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002750","article-title":"Calcium antagonists as an add-on therapy for drug-resistant epilepsy","author":"Chaisewikul","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002750.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T10:32:42Z","timestamp":1725705162000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002750.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,3,28]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002750.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,28]]}}}